Incremental value of cell block preparation over conventional smear alone in the evaluation of EUS-FNA

s / Pancreatology were still receiving FOLFIRINOX on cycles 5–9 of the therapy. One patient (5.6%) had confirmed complete response, four (22.2%) had confirmed partial responses, and five (27.8%) stable diseases, resulting in a rate of disease control of 55.6% (95% CI, 33.3–77.8%). The median progression-free survival was 2.8 months (95% CI, 1.5–4.1 months). Median overall survival was 8.4 months (95% CI, 6.5–10.3 months). The tolerance of treatment was acceptable with seven patients (38.9%) experiencing grade 3–4 neutropenia, including two febrile neutropenia. Grade 3 or 4 non-hematologic adverse events included nausea (38.9%), and vomiting (16.7%). Conclusions: These results suggest the modest clinical activity on efficacy and acceptable toxicity profile with the FOLFIRINOX regimen as second-line treatment after gemcitabine failure in selected patients with advanced pancreatic adenocarcinoma and good performance status.